| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumor
|
Rutkowski, Piotr Lukasz
|
|
|
225 |
C |
p.
|
artikel
|
| 2 |
Borrowing from the past to test the future: Innovative approaches to prospective clinical trials in rare cancers
|
Cornelissen, Jan J.
|
|
|
225 |
C |
p.
|
artikel
|
| 3 |
Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study
|
O'Reilly, David
|
|
|
225 |
C |
p.
|
artikel
|
| 4 |
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
|
Mandalà, Mario
|
|
|
225 |
C |
p.
|
artikel
|
| 5 |
Conditional survival of children, adolescents and young adults (0–24 years) diagnosed with leukaemia during 2000–2014 world-wide: (CONCORD-3)
|
Ssenyonga, N.
|
|
|
225 |
C |
p.
|
artikel
|
| 6 |
Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis
|
Monaca, Federico
|
|
|
225 |
C |
p.
|
artikel
|
| 7 |
Corrigendum to” Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes,” [Eur J Cancer 2025 May 15:221:115404.]
|
Fortuny, Marta
|
|
|
225 |
C |
p.
|
artikel
|
| 8 |
Current evidence of low-dose CT screening benefit
|
Yip, Rowena
|
|
|
225 |
C |
p.
|
artikel
|
| 9 |
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study
|
Grünwald, Viktor
|
|
|
225 |
C |
p.
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
225 |
C |
p.
|
artikel
|
| 11 |
Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies
|
Jiménez-Labaig, Pablo
|
|
|
225 |
C |
p.
|
artikel
|
| 12 |
Exploring isolated tumor cells entity in endometrial cancer
|
Capozzi, Vito Andrea
|
|
|
225 |
C |
p.
|
artikel
|
| 13 |
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101)
|
Knauer, Michael
|
|
|
225 |
C |
p.
|
artikel
|
| 14 |
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors
|
Özkan, Asli
|
|
|
225 |
C |
p.
|
artikel
|
| 15 |
Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacy
|
Vion, Roman
|
|
|
225 |
C |
p.
|
artikel
|
| 16 |
Letter Re: Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy
|
Sahin, Taha Koray
|
|
|
225 |
C |
p.
|
artikel
|
| 17 |
Letter Re: Ossifying fibromyxoid tumours: A case series subtitle: Successful control of a PHF1::TFE3-rearranged metastatic malignant ossifying fibromyxoid tumor using cabozantinib
|
Lee, Hyun
|
|
|
225 |
C |
p.
|
artikel
|
| 18 |
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS
|
Gobbini, Elisa
|
|
|
225 |
C |
p.
|
artikel
|
| 19 |
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
|
Lipson, Evan J.
|
|
|
225 |
C |
p.
|
artikel
|
| 20 |
Pan-RAS inhibitor after KRASG12C treatment in pancreatic cancer?
|
Swales, Léa
|
|
|
225 |
C |
p.
|
artikel
|
| 21 |
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)
|
Iannantuono, Giovanni Maria
|
|
|
225 |
C |
p.
|
artikel
|
| 22 |
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
|
Blons, H.
|
|
|
225 |
C |
p.
|
artikel
|
| 23 |
Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysis
|
Laguna, Juan Carlos
|
|
|
225 |
C |
p.
|
artikel
|
| 24 |
Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial
|
Ganame, S.
|
|
|
225 |
C |
p.
|
artikel
|
| 25 |
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
|
DeTemple, Viola K.
|
|
|
225 |
C |
p.
|
artikel
|
| 26 |
Regulation of epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: Role of key molecules in tumor differentiation and therapy
|
Ling, Qi
|
|
|
225 |
C |
p.
|
artikel
|
| 27 |
Response to Letter to the Editor on "Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy"
|
Monaca, Federico
|
|
|
225 |
C |
p.
|
artikel
|
| 28 |
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
|
Ledermann, Jonathan A.
|
|
|
225 |
C |
p.
|
artikel
|
| 29 |
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results
|
Coleman, Robert L.
|
|
|
225 |
C |
p.
|
artikel
|
Tijdschrift beschrijving